Rochelle-Leigh (Shelley) Rosenberg
Overview
Rochelle-Leigh (Shelley) Rosenberg is a trial and appellate litigator. As a partner in Crowell & Moring's Washington, D.C. office, she practices in the Litigation and Health Care groups and is also a member of the Administrative Law & Regulatory Practice, which is a cross-section of all of the firm's regulatory groups. Shelley's practice primarily includes representing managed care organizations and other health care entities in various litigation matters.
Career & Education
- University of Michigan, B.A., Phi Beta Kappa, public policy, 2010
- Harvard Law School, J.D., 2013
- District of Columbia
- Virginia
- U.S. District Court for the Eastern District of Michigan
- U.S. District Court for the Southern District of New York
- U.S. District Court for the Eastern District of Virginia
- U.S. District Court for the Western District of Virginia
Rochelle-Leigh (Shelley)'s Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Firm News | 5 min read | 08.20.26
Firm News | 2 min read | 08.13.26
Three Crowell & Moring Partners Named to BTI Client Service All-Stars 2026
Client Alert | 3 min read | 07.21.25
Not So Surprising: The Fifth Circuit Finds No Private Right of Action in the No Surprises Act
Representative Matters
- Representing a Fortune 50 health insurance company in arbitration and trial against a major Maryland hospital system regarding payment of claims.
- Successfully defending a Fortune 50 health insurance company regarding member benefits in Virginia General District Court.
- Defending eight health insurance companies in multi-district litigation (MDL) class actions asserting nationwide and state antitrust claims.
- Representing a large health insurer in multiple arbitration proceedings involving a Medicare Advantage dispute.
- Successfully trying case on behalf of leading health services company involving fraud and breach of contract claims related to the design, build, and operation of a health plan.
- Representing a large health care client in False Claims Act case initiated by qui-tam relator.
- Successfully representing a health care provider before the District of Columbia Court of Appeals in arguing that an administrative law judge (ALJ) with the D.C. Office of Administrative Hearings applied the wrong standard of review in reversing a favorable agency order, resulting in reversal of the ALJ decision.
Rochelle-Leigh (Shelley)'s Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Firm News | 5 min read | 08.20.26
Firm News | 2 min read | 08.13.26
Three Crowell & Moring Partners Named to BTI Client Service All-Stars 2026
Client Alert | 3 min read | 07.21.25
Not So Surprising: The Fifth Circuit Finds No Private Right of Action in the No Surprises Act
Recognition
- Best Lawyers in America: Ones to Watch: Commercial Litigation, Health Care Law, 2026-2027
- BTI Consulting Group: Client Service All-Star, 2026
- Washington D.C. Super Lawyers: Rising Star - Health Care, 2016-2021
- American Health Lawyers Association: Pro Bono Champion, 2015
- Nominated by Crowell & Moring for its annual "George Bailey" Awards, 2016
Rochelle-Leigh (Shelley)'s Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Firm News | 5 min read | 08.20.26
Firm News | 2 min read | 08.13.26
Three Crowell & Moring Partners Named to BTI Client Service All-Stars 2026
Client Alert | 3 min read | 07.21.25
Not So Surprising: The Fifth Circuit Finds No Private Right of Action in the No Surprises Act
Insights
How to Better Manage Discovery and Save Costs in the Era of Expanding Data
|06.01.18
Legal Management
How to Limit Litigation Risk from the Increased Use of Chat Programs During the COVID-19 Pandemic
|06.12.20
Crowell & Moring’s Data Law Insights
Federal District Court Judge Vacates Arkansas and Kentucky’s Medicaid Work Requirements
|04.01.19
Crowell & Moring's Health Law Blog
Crowell's Long-Term Care Policy Update—Recapping the Discussions and Debates
|05.04.15
Crowell & Moring’s Health Law Blog
- |
01.09.15
Crowell & Moring's Health Law Blog
Rochelle-Leigh (Shelley)'s Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Firm News | 5 min read | 08.20.26
Firm News | 2 min read | 08.13.26
Three Crowell & Moring Partners Named to BTI Client Service All-Stars 2026
Client Alert | 3 min read | 07.21.25
Not So Surprising: The Fifth Circuit Finds No Private Right of Action in the No Surprises Act




